Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia

11/9 Late treatment study

Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008 (Peer Reviewed)
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia

Source PDF Share Tweet

Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.

Khamis et al., 11/9/2020, peer-reviewed, 11 authors.

All 21 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit

Aspirin	Metformin
Bamlanivimab	Molnupiravir
Bromhexine	Nigella Sativa
Budesonide	Nitazoxanide
Casirivimab/i..	Povidone-Iod..
Colchicine	Probiotics
Conv. Plasma	Proxalutamide
Curcumin	Quercetin
Favipiravir	Remdesivir
Fluvoxamine	Sotrovimab
Hydroxychloro..	Vitamin A
Iota-carragee..	Vitamin C
Ivermectin	Vitamin D
Melatonin	Zinc

Other	Adoption